Andrew D. Ashe - 11 Feb 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
President, Chief Operating Officer
Signature
/s/ Andrew Ashe
Issuer symbol
VERV
Transactions as of
11 Feb 2022
Net transactions value
$0
Form type
4
Filing time
15 Feb 2022, 07:56:49 UTC
Previous filing
06 Dec 2021
Next filing
29 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 11 Feb 2022 Common Stock 125,000 $30.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 11, 2022. 25% of the shares underlying the option will vest on February 11, 2023, and the remainder are scheduled to vest in equal monthly installments thereafter until February 11, 2026.

Remarks:

President, Chief Operating Officer